Roche's triplet in­volv­ing Tecen­triq clears the PFS bar for melanoma when added to BRAF/MEK com­bo

In a “check the box” ex­er­cise, Roche said it has shown that adding Tecen­triq to a com­bo of Cotel­lic and Zelb­o­raf was ef­fec­tive in ex­tend­ing pro­gres­sion-free sur­vival in melanoma pa­tients com­pared to place­bo plus the two drugs.

Pa­tients with pre­vi­ous­ly un­treat­ed BRAF V600 mu­ta­tions were re­cruit­ed to the Phase III study, dubbed IM­spire150.

Cotel­lic (which was ini­tial­ly de­vel­oped by Roche part­ner Ex­elix­is) and Zelb­o­raf are al­ready ap­proved to treat BRAF V600E or V600K mu­ta­tion-pos­i­tive un­re­sectable or metasta­t­ic melanoma. While the lat­ter blocks some BRAF ki­nas­es, the for­mer is be­lieved to help break treat­ment re­sis­tance by al­so in­hibit­ing MEK1/2.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER